Oculis Holding AG Ordinary shares (OCS)
Oculis Holding AG is a biomedical company focused on developing innovative ophthalmic therapies. Specializing in treatments for eye diseases, the company leverages advanced drug delivery technologies to address unmet medical needs in ophthalmology. Positioned within the pharmaceutical industry, Oculis aims to improve patient outcomes through its research and development efforts in eye care.
Company News
Oculis, in collaboration with EURETINA, announced Dr. Prithvi Ramtohul as the winner of the 2025 Ramin Tadayoni Award, honoring an exceptional postgraduate scholar in retinal research who is studying neuronal excitability in retinal ganglion cells.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. JP Morgan slashed the price target for Nucor Corporation (NYSE:NUE) from $190 to $180. JP Morgan analyst Bill Peterson maintained a Neutral rating. Nucor shares fell 2.3% to close at $157.31 on Monday. See how other analysts view this stock. Needham increased the price target for PAR Technology Corporation (NYSE:PAR) from $53 to $57. Needham analyst Mayank Tandon maintained a Buy rating. PAR Technology shares gained 6.1% to close at $45.57 on Monday. See how other analysts view this stock. Wedbush slashed Darden Restaurants, Inc. (NYSE:DRI) price target from $181 to $170. Wedbush analyst Nick Setyan maintained an Outperform rating. Darden shares fell 0.6% to close at $147.68 on Monday. See how other analysts view this stock. Baird raised the price target for First Solar, ...Full story available on Benzinga.com
The consensus price target hints at a 152.8% upside potential for Oculis Holding AG (OCS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.